Compare Stocks Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities. Stocks to Compare Sections All Sections Selected Performance Chart Price & Volume MarketRank Analyst Ratings Sales & Book Value Profitability & Earnings Dividends Debt Ownership Miscellaneous Headlines About Compare NASDAQ:IBB NASDAQ:REGN On This Page Performance ChartPrice & VolumeMarketRank™Analyst RatingsSales & Book ValueProfitability & EarningsDividendsDebtOwnershipMiscellaneousHeadlinesAbout Comparison Ideas Stock Ideas Comparative Price Performance Over Time1 day7 days30 days90 days365 daysCompare Price & VolumeCompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's VolumeIBBiShares Biotechnology ETF$189.58-1.3%$176.32$128.84▼$199.05$9.34B0.71.63 million shs1.94 million shsREGNRegeneron Pharmaceuticals$663.09-0.2%$644.42$541.00▼$821.11$70.25B0.24939,951 shs604,985 shsThe Infrastructure's Backbone: 10 Stocks Powering the AI BuildoutThe AI boom extends far beyond the biggest tech names. Discover 10 companies supplying the memory, storage, networking, semiconductor manufacturing, and power infrastructure that make AI possible. Learn where the next wave of AI investment opportunities may emerge—and the key risks investors should watch as the global AI buildout accelerates.Get This Free ReportCompare Price PerformanceCompany1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year PerformanceIBBiShares Biotechnology ETF0.00%-1.86%+12.54%+11.54%+45.95%REGNRegeneron Pharmaceuticals0.00%+1.57%+8.56%-10.98%+17.05%Compare Price & VolumeCompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's VolumeIBBiShares Biotechnology ETF$189.58-1.3%$176.32$128.84▼$199.05$9.34B0.71.63 million shs1.94 million shsREGNRegeneron Pharmaceuticals$663.09-0.2%$644.42$541.00▼$821.11$70.25B0.24939,951 shs604,985 shsThe Infrastructure's Backbone: 10 Stocks Powering the AI BuildoutThe AI boom extends far beyond the biggest tech names. Discover 10 companies supplying the memory, storage, networking, semiconductor manufacturing, and power infrastructure that make AI possible. Learn where the next wave of AI investment opportunities may emerge—and the key risks investors should watch as the global AI buildout accelerates.Get This Free ReportCompare Price PerformanceCompany1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year PerformanceIBBiShares Biotechnology ETF0.00%-1.86%+12.54%+11.54%+45.95%REGNRegeneron Pharmaceuticals0.00%+1.57%+8.56%-10.98%+17.05%Compare Analyst ForecastsCompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current PriceIBBiShares Biotechnology ETF 2.70Moderate Buy$189.58N/AREGNRegeneron Pharmaceuticals 2.70Moderate Buy$787.6718.79% UpsideCurrent Analyst Ratings BreakdownLatest REGN and IBB Analyst RatingsDateCompanyBrokerageActionRatingPrice TargetDetails7/9/2026REGNRegeneron Pharmaceuticals Piper SandlerSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingLower Price TargetOverweight$855.00 ➝ $854.007/8/2026REGNRegeneron Pharmaceuticals Morgan StanleySubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingLower Price TargetEqual Weight$788.00 ➝ $730.007/7/2026REGNRegeneron Pharmaceuticals Royal Bank Of CanadaSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingLower Price TargetSector Perform$707.00 ➝ $696.007/7/2026REGNRegeneron Pharmaceuticals BenchmarkSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingUpgradeHold ➝ Buy$185.007/7/2026REGNRegeneron Pharmaceuticals Truist FinancialSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingLower Price TargetBuy$778.00 ➝ $769.007/6/2026REGNRegeneron Pharmaceuticals HSBCSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingLower Price TargetBuy$990.00 ➝ $880.007/6/2026REGNRegeneron Pharmaceuticals Cantor FitzgeraldSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingLower Price TargetOverweight$785.00 ➝ $750.006/24/2026REGNRegeneron Pharmaceuticals Weiss RatingsSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingReiterated RatingHold (C)5/19/2026REGNRegeneron Pharmaceuticals Canaccord Genuity GroupSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingLower Price TargetBuy$1,057.00 ➝ $875.005/18/2026REGNRegeneron Pharmaceuticals BMO Capital MarketsSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingLower Price TargetOutperform$900.00 ➝ $730.00(Data available from 7/13/2023 forward. View 10+ years of historical ratings with our analyst ratings screener.)Compare Sales & Book ValueCompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/BookIBBiShares Biotechnology ETFN/AN/AN/AN/AN/AN/AREGNRegeneron Pharmaceuticals$14.34B4.89$41.89 per share15.83$295.66 per share2.24Compare Profitability & EarningsCompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings DateIBBiShares Biotechnology ETFN/AN/AN/AN/AN/AN/AN/AN/AN/AREGNRegeneron Pharmaceuticals$4.50B$41.0416.1615.921.4729.65%13.16%10.17%7/30/2026 (Estimated)Latest REGN and IBB EarningsDateQuarterCompanyConsensus EstimateReported EPSBeat/MissGap EPSRevenue EstimateActual RevenueDetails7/30/2026Q2 2026REGNRegeneron Pharmaceuticals$10.54N/AN/AN/A$3.80 billionN/A4/29/2026Q1 2026REGNRegeneron Pharmaceuticals$8.91$9.47+$0.56$6.75$3.48 billion$3.61 billionCompare DividendsCompanyAnnual PayoutDividend Yield5-Year Annualized Dividend GrowthPayout RatioYears of Consecutive GrowthIBBiShares Biotechnology ETF$0.410.22%N/AN/AN/AREGNRegeneron Pharmaceuticals$3.760.57%N/A9.16%N/ALatest REGN and IBB DividendsAnnouncementCompanyPeriodAmountYieldEx-Dividend DateRecord DatePayable Date6/12/2026IBBiShares Biotechnology ETFQuarterly$0.02380.06%6/15/20266/15/20266/18/20264/29/2026REGNRegeneron Pharmaceuticalsquarterly$0.940.58%5/20/20265/20/20266/4/2026(Data available from 1/1/2013 forward)Compare DebtCompanyDebt-to-Equity RatioCurrent RatioQuick RatioIBBiShares Biotechnology ETFN/AN/AN/AREGNRegeneron Pharmaceuticals0.063.572.96Compare OwnershipInstitutional OwnershipCompanyInstitutional OwnershipIBBiShares Biotechnology ETF62.45%REGNRegeneron Pharmaceuticals83.31%Insider OwnershipCompanyInsider OwnershipIBBiShares Biotechnology ETFN/AREGNRegeneron Pharmaceuticals6.97%Compare Miscellaneous StatsCompanyEmployeesShares OutstandingFree FloatOptionableIBBiShares Biotechnology ETFN/A48.65 millionN/AOptionableREGNRegeneron Pharmaceuticals15,410105.72 million98.35 millionOptionableREGN and IBB HeadlinesRecent News About These CompaniesDisappointing Trial Results Hurt Regeneron Pharmaceuticals (REGN) in Q2July 13 at 12:19 PM | finance.yahoo.comDisappointing Trial Results Hurt Regeneron Pharmaceuticals (REGN) in Q2July 13 at 11:31 AM | insidermonkey.comRegeneron Pharmaceuticals, Inc. $REGN Stock Holdings Reduced by Applied Finance Capital Management LLCJuly 13 at 3:12 AM | marketbeat.comUNIVEST FINANCIAL Corp Has $10.98 Million Position in Regeneron Pharmaceuticals, Inc. $REGNJuly 12 at 1:20 PM | marketbeat.comRegeneron Pharmaceuticals, Inc. $REGN Shares Sold by Sovran Advisors LLCJuly 12 at 1:11 PM | marketbeat.comOsprey Private Wealth LLC Has $7.29 Million Stock Holdings in Regeneron Pharmaceuticals, Inc. $REGNJuly 11 at 11:03 AM | marketbeat.comRegeneron Pharmaceuticals, Inc. $REGN Shares Sold by Candriam S.C.A.July 11 at 9:19 AM | marketbeat.comRegeneron Pharmaceuticals, Inc. $REGN Shares Sold by Sumitomo Mitsui Trust Group Inc.July 10 at 5:27 AM | marketbeat.comRegeneron Pharmaceuticals (NASDAQ:REGN) Price Target Lowered to $854.00 at Piper SandlerJuly 10 at 3:23 AM | americanbankingnews.comAnalysts Offer Insights on Healthcare Companies: Regeneron (REGN), Newron Pharmaceuticals SpA (OtherNWPHF) and Boston Scientific (BSX)July 9, 2026 | theglobeandmail.comPiper Sandler Issues Pessimistic Forecast for Regeneron Pharmaceuticals (NASDAQ:REGN) Stock PriceJuly 9, 2026 | marketbeat.comWhy Investors Need to Take Advantage of These 2 Medical Stocks NowJuly 9, 2026 | zacks.comRegeneron Pharmaceuticals (NASDAQ:REGN) Price Target Cut to $730.00 by Analysts at Morgan StanleyJuly 9, 2026 | americanbankingnews.comIs Regeneron Pharmaceuticals, Inc. (REGN) Stock Still a Biotech Leader After Analyst Price Target Cut?July 8, 2026 | finance.yahoo.comRegeneron Pharmaceuticals (NASDAQ:REGN) Price Target Lowered to $730.00 at Morgan StanleyJuly 8, 2026 | marketbeat.comArthur Ryan Sells 200 Shares of Regeneron Pharmaceuticals (NASDAQ:REGN) StockJuly 8, 2026 | insidertrades.comRegeneron Pharmaceuticals (NASDAQ:REGN) Director Sells 200 SharesJuly 7, 2026 | marketbeat.comWill Regeneron (REGN) Beat Estimates Again in Its Next Earnings Report?July 7, 2026 | zacks.comJim Cramer Calls Biotech “The Hottest Group in the Market” as He Predicts “Deals Are Going to Be Flooding the Market”July 7, 2026 | 247wallst.comRoyal Bank Of Canada Has Lowered Expectations for Regeneron Pharmaceuticals (NASDAQ:REGN) Stock PriceJuly 7, 2026 | marketbeat.comRegeneron Pharmaceuticals, Inc. $REGN Shares Sold by Swedbank ABJuly 7, 2026 | marketbeat.comNew MarketBeat Followers Over TimeMedia Sentiment Over Time Top HeadlinesView All HeadlinesMission Control: Floating In SpaceX's Record-Breaking OrbitBy Jeffrey Neal Johnson | June 15, 2026Gravity Check: Houston, SpaceX Has a Valuation ProblemBy Jeffrey Neal Johnson | June 16, 20265 Tech Stocks to Buy on the July PullbackBy Thomas Hughes | June 29, 2026The Biotech Sector Looks Ready for a Multi-Year Breakout—Here's What to Watch.By Ryan Hasson | June 23, 20265 Places Investors Can Hide If the AI Trade Keeps CrackingBy Ryan Hasson | June 29, 2026REGN and IBB Company DescriptionsiShares Biotechnology ETF NASDAQ:IBB$189.58 -2.48 (-1.29%) As of 04:00 PM EasterniShares Nasdaq Biotechnology ETF (the Fund), formerly iShares Nasdaq Biotechnology Index Fund, is an exchange-traded fund (ETF). The Fund seeks investment results that correspond generally to the price and yield performance of the NASDAQ Biotechnology Index (the Index). The Index contains securities of NASDAQ listed companies that are classified according to the Industry Classification Benchmark as either biotechnology or pharmaceuticals, which also meet other eligibility criteria determined by NASDAQ. The Fund invests in a representative sample of securities included in the Index that collectively has an investment profile similar to the Index. Due to the use of representative sampling, the Fund may or may not hold all of the securities that are included in the Index. The Fund’s investment advisor is BlackRock Fund Advisors, which is indirectly owned by BlackRock, Inc.Regeneron Pharmaceuticals NASDAQ:REGN$663.09 -1.43 (-0.22%) Closing price 04:00 PM EasternExtended Trading$664.00 +0.91 (+0.14%) As of 07:59 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more.Regeneron Pharmaceuticals, Inc. discovers, invents, develops, manufactures, and commercializes medicines for treating various diseases worldwide. The company's products include EYLEA injection to treat wet age-related macular degeneration and diabetic macular edema; myopic choroidal neovascularization; diabetic retinopathy; neovascular glaucoma; and retinopathy of prematurity. It also provides Dupixent injection to treat atopic dermatitis and asthma in adults and pediatrics; Libtayo injection to treat metastatic or locally advanced cutaneous squamous cell carcinoma; Praluent injection for heterozygous familial hypercholesterolemia or clinical atherosclerotic cardiovascular disease in adults; REGEN-COV for covid-19; and Kevzara solution for treating rheumatoid arthritis in adults. In addition, the company offers Inmazeb injection for infection caused by Zaire ebolavirus; ARCALYST injection for cryopyrin-associated periodic syndromes, including familial cold auto-inflammatory syndrome and muckle-wells syndrome; and ZALTRAP injection for intravenous infusion to treat metastatic colorectal cancer; and develops product candidates for treating patients with eye, allergic and inflammatory, cardiovascular and metabolic, infectious, and rare diseases; and cancer, pain, and hematologic conditions. It has collaboration with Mammoth Biosciences, Inc. to research, develop and commercialize in vivo CRISPR-based gene editing therapies for multiple tissues and cell types. The company was incorporated in 1988 and is headquartered in Tarrytown, New York. More Stock Comparisions from MarketBeat Stock Comparison Ideas (A-K)5GAgricultureAirlineAmerica FirstApparelArtificial IntelligenceAutomotiveBankBiotechBitcoinBlockchainBlue ChipCanadianCannabisCasinoChatGPTChineseCloud StorageCryptocurrencyCybersecurityDefenseDividendDow 30DroneEcommerceElectric VehiclesEnergyEntertainmenteSportsEV ChargingFertilizerFlying CarGoldGroceryGrowthHealthcareHigh DividendHotelStock Comparison Ideas (L-Z)Large CapLeisureLithiumMade In AmericaMagnificent SevenMega CapMemeMetaverseMid CapMiningMusic IndustryNanotechnologyNFTNuclear EnergyOilPharmaceuticalQuantum ComputingRenewable EnergyRestaurantRetailSemiconductorSilverSocial MediaSolarSpaceTechnologyTelecomToyUraniumUtilityVideo GameVirtual RealityWallStreetBets More Stock Ideas from MarketBeat Stock Lists 5G Stocks Biotech Stocks Blue Chip Stocks DOW 30 Stocks FAANG Stocks Gold Stocks Large Cap Stocks Lumber Stocks Marijuana Stocks Micro Cap Stocks Oil Stocks REITs Small Cap Stocks SPACs Travel Stocks Trillion Dollar Stocks Water Stocks Warren Buffett Stocks Low Priced Stocks Penny Stock List Popular Penny Stocks Top Stocks Today Stocks on Sale Stocks Under $0.05 Stocks Under $0.10 Stocks Under $0.25 Stocks Under $0.50 Stocks Under $1 Stocks Under $2 Stocks Under $3 Stocks Under $5 Stocks Under $10 Stocks Under $20 Stocks Under $30 Stocks Under $50 Stocks By Exchange NASDAQ Stocks NYSE Stocks NYSEAMERICAN Stocks NYSEARCA Stocks NYSEMKT Stocks OTCMKTS Stocks TSX Stocks TSXV Stocks LSE Stocks BATS Stocks Latest Stock Ideas The SK Hynix IPO and 2027’s AI Memory Squeeze Why Welltower's Growth Story Might Outrun Its Rich Valuation Why Micron Is Doubling Down While the HBM Shortage Persists AMD's 5C Deal Positions It as a Direct NVIDIA Rival China's Helium Ban Could Reshape the AI Supply Chain The Phase 3 Failure That Sent Biotech Winners and Losers in Opposite Directions Analysts See Major Upside for These 5 Stocks One Short- and One Long-Term ETF for Quantum Computing Bulls Unlock superior investment research and tools. Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools and reports. Get MarketBeat All Access MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In Email Me a Login Link or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
